Celldex Therapeutics Overview
Pro stress-test →Celldex Therapeutics is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of cold urticaria and symptomatic dermographism—the mast cell.
Strategic Profile
Pro stress-test →Barzo is uniquely positioned as a "pipeline in a drug," targeting multiple mast cell diseases and commanding potential premium pricing. Management suggests that barzo's durable efficacy—extending beyond a year of dosing—could support substantially higher reimbursement, comparable to Dupixent's $60,000 annual cost.
Competitive Landscape
Pro stress-test →Celldex is pioneering new horizons in immunology to deliver life-changing therapies, pursuing novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve lives of patients with allergic, inflammatory and autoimmune disorders. The mast cell-targeting immunology space includes competitors developing alternative approaches to urticaria and related conditions.
Industry Context
Celldex Therapeutics operates in Biopharmaceutical - Immunotherapy and Monoclonal Antibodies.
Key facts
Headquarters: Hampton, New Jersey, US · Revenue: $0.12M (Q4 2025) · Market cap: $2.02B